CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 5,161 enrolled
Drug / intervention
mRNA-1273.211 +8 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04927065
NCT04927065Phase 3Completed
CompareCT.gov

A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants

ModernaTX, Inc.·interventional·Posted Jun 15, 2021·Updated Feb 28, 2025

In Brief

A Phase 3 clinical trial evaluating mRNA-1273.211, mRNA-1273, and 7 other interventions for SARS-CoV-2. Completed, enrolled 5,161 participants across 23 sites.

Detailed Summary

This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJun 15, 2021
Enrollment StartMay 28, 2021
Primary CompletionNov 17, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.0 years ago

Interventions

mRNA-1273.211biological

Sterile liquid for injection

mRNA-1273biological

Sterile liquid for injection

mRNA-1273.617.2biological

Sterile liquid for injection

mRNA-1273.213biological

Sterile liquid for injection

mRNA-1273.529biological

Sterile liquid for injection

mRNA-1273.214biological

Sterile liquid for injection

mRNA-1273.222biological

Sterile liquid for injection

mRNA-1273.815biological

Sterile liquid for injection

mRNA-1273.231biological

Sterile liquid for injection